Health · 2 views
Ianalumab's Road to Approval for Sjogren's Looks Bumpier
Health 
Story intelligence
Coverage Single outlet Single-outlet story
Views 2 Community interest
Brief read Under 1 min brief 35 words
Summary
(MedPage Today) -- Findings from a pair of randomized trials in Sjögren's disease with the anti-B cell biologic ianalumab have now been published and it's no longer clear that they're sufficient to support regulatory approvals.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- STAT+: CMS extends fraud crackdown to New York’s adult day care programContinue reading
- Invisible infrared light creates green letters that are less prone to blurContinue reading
- Psilocybin Tied to Lower Inflammation in Parkinson's TrialContinue reading
- STI rates drop following antibiotic use recommendations for gay and bisexual menContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow